Ashok Anushruti, Andrabi Syed Suhail, Mansoor Saffar, Kuang Youzhi, Kwon Brian K, Labhasetwar Vinod
Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Department of Orthopaedics, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Antioxidants (Basel). 2022 Feb 17;11(2):408. doi: 10.3390/antiox11020408.
Free radicals are formed as a part of normal metabolic activities but are neutralized by the endogenous antioxidants present in cells/tissue, thus maintaining the redox balance. This redox balance is disrupted in certain neuropathophysiological conditions, causing oxidative stress, which is implicated in several progressive neurodegenerative diseases. Following neuronal injury, secondary injury progression is also caused by excessive production of free radicals. Highly reactive free radicals, mainly the reactive oxygen species (ROS) and reactive nitrogen species (RNS), damage the cell membrane, proteins, and DNA, which triggers a self-propagating inflammatory cascade of degenerative events. Dysfunctional mitochondria under oxidative stress conditions are considered a key mediator in progressive neurodegeneration. Exogenous delivery of antioxidants holds promise to alleviate oxidative stress to regain the redox balance. In this regard, natural and synthetic antioxidants have been evaluated. Despite promising results in preclinical studies, clinical translation of antioxidants as a therapy to treat neurodegenerative diseases remains elusive. The issues could be their low bioavailability, instability, limited transport to the target tissue, and/or poor antioxidant capacity, requiring repeated and high dosing, which cannot be administered to humans because of dose-limiting toxicity. Our laboratory is investigating nanoparticle-mediated delivery of antioxidant enzymes to address some of the above issues. Apart from being endogenous, the main advantage of antioxidant enzymes is their catalytic mechanism of action; hence, they are significantly more effective at lower doses in detoxifying the deleterious effects of free radicals than nonenzymatic antioxidants. This review provides a comprehensive analysis of the potential of antioxidant therapy, challenges in their clinical translation, and the role nanoparticles/drug delivery systems could play in addressing these challenges.
自由基作为正常代谢活动的一部分而形成,但会被细胞/组织中存在的内源性抗氧化剂中和,从而维持氧化还原平衡。在某些神经病理生理条件下,这种氧化还原平衡会被打破,导致氧化应激,这与几种进行性神经退行性疾病有关。神经元损伤后,自由基的过量产生也会导致继发性损伤的进展。高反应性自由基,主要是活性氧(ROS)和活性氮(RNS),会损害细胞膜、蛋白质和DNA,从而引发一系列自我传播的炎症性退行性事件。氧化应激条件下功能失调的线粒体被认为是进行性神经退行性变的关键介质。外源性给予抗氧化剂有望减轻氧化应激,恢复氧化还原平衡。在这方面,天然和合成抗氧化剂都已得到评估。尽管在临床前研究中取得了令人鼓舞的结果,但抗氧化剂作为治疗神经退行性疾病的疗法在临床转化方面仍然难以实现。问题可能在于它们的生物利用度低、稳定性差、向靶组织的转运有限和/或抗氧化能力差,需要重复高剂量给药,而由于剂量限制毒性,无法用于人类。我们实验室正在研究纳米颗粒介导的抗氧化酶递送,以解决上述一些问题。除了是内源性的之外,抗氧化酶的主要优点是其催化作用机制;因此,与非酶抗氧化剂相比,它们在较低剂量下就能更有效地解毒自由基的有害影响。这篇综述全面分析了抗氧化疗法的潜力、其临床转化中的挑战以及纳米颗粒/药物递送系统在应对这些挑战中可能发挥的作用。